The Paris Technology and Life Sciences team advised Depixus, a French life science tools company, on its €30.6 million Series A financing led by Bpifrance and Lansdowne Partners.
Depixus is undertaking commercial development of a disruptive new technology for the fast, accurate, and inexpensive extraction of sequence and epigenetic information from long individual molecules of DNA and RNA. Its MAGNA technology goes beyond decoding the static genetic code to reveal the dynamics of the genome that control health and disease.
The Goodwin team was led by Anne-Charlotte Rivière and Johann Gandilhon on corporate aspects.